Syros Pharmaceuticals Inc. (NASDAQ:SYRS) issued its earnings results on Monday. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.12.

Syros Pharmaceuticals (NASDAQ:SYRS) opened at 12.75 on Tuesday. Syros Pharmaceuticals has a 52-week low of $8.16 and a 52-week high of $21.50. The firm’s market capitalization is $298.02 million. The company’s 50-day moving average is $13.60 and its 200-day moving average is $13.04.

SYRS has been the subject of several analyst reports. HC Wainwright initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 18th. They issued a “neutral” rating and a $10.00 target price for the company. Piper Jaffray Cos. initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “overweight” rating and a $20.00 target price for the company. Wedbush initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating and a $18.00 target price for the company. JMP Securities initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating and a $22.00 target price for the company. Finally, Cowen and Company initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating for the company. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $17.50.

A number of institutional investors have recently bought and sold shares of SYRS. California State Teachers Retirement System bought a new position in Syros Pharmaceuticals during the third quarter valued at $137,000. Morgan Stanley acquired a new position in shares of Syros Pharmaceuticals during the third quarter worth $469,000. Weiss Multi Strategy Advisers LLC acquired a new position in shares of Syros Pharmaceuticals during the second quarter worth $832,000. Finally, Aisling Capital LLC acquired a new position in shares of Syros Pharmaceuticals during the second quarter worth $16,490,000. Institutional investors own 54.63% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.